RhumbLine Advisers’s Sionna Therapeutics SION Stock Holding History

RhumbLine Advisers’s Portfolio SION Stock Details SION Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$115K	Sell	21,852 -457	-2%	-$10.5K	﹤0.01%	3479
2026 Q2	$981K	Buy	22,309 +4,001	+22%	+$160K	﹤0.01%	2327
2026 Q1	$734K	Buy	18,308 +614	+3%	+$23.4K	﹤0.01%	2368
2025 Q4	$728K	Buy	17,694 +454	+3%	+$17.2K	﹤0.01%	2413
2025 Q3	$507K	Sell	17,240 -430	-2%	-$9.36K	﹤0.01%	2691
2025 Q2	$307K	Buy	+17,670	New	+$232K	﹤0.01%	2974

Other funds holding SION

Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

RhumbLine Advisers's SION Position: Q3 2026 in Review

RhumbLine Advisers reduced its Sionna Therapeutics (SION) stake by 2% in Q3 2026, selling an estimated $10.5K and leaving 21,852 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #3479.

RhumbLine Advisers first reported a position in SION in Q2 2025 and has held it in 6 quarters since. The position peaked at $981K in Q2 2026. 87 funds tracked by Wall St. Rank hold SION as of Q3 2026.

RhumbLine Advisers held 21,852 shares of Sionna Therapeutics worth $115K as of Q3 2026.
RhumbLine Advisers sold 457 Sionna Therapeutics shares in Q3 2026, an estimated $10.5K.
Sionna Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3479 holding.
RhumbLine Advisers first reported a position in Sionna Therapeutics in Q2 2025 and has held it in 6 quarters since.
RhumbLine Advisers's Sionna Therapeutics position peaked at $981K in Q2 2026.
87 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.